Thermo Fisher Scientific Inc. (NYSE:TMO) Position Lowered by SeaBridge Investment Advisors LLC

SeaBridge Investment Advisors LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,571 shares of the medical research company’s stock after selling 511 shares during the period. Thermo Fisher Scientific comprises about 1.2% of SeaBridge Investment Advisors LLC’s investment portfolio, making the stock its 24th biggest holding. SeaBridge Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $5,499,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Marietta Wealth Management LLC raised its stake in Thermo Fisher Scientific by 5.3% during the fourth quarter. Marietta Wealth Management LLC now owns 14,027 shares of the medical research company’s stock worth $7,297,000 after acquiring an additional 708 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Thermo Fisher Scientific by 37.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,891 shares of the medical research company’s stock worth $984,000 after acquiring an additional 519 shares during the period. Destiny Wealth Partners LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $220,000. Everett Harris & Co. CA raised its stake in Thermo Fisher Scientific by 2.6% during the fourth quarter. Everett Harris & Co. CA now owns 14,506 shares of the medical research company’s stock worth $7,546,000 after acquiring an additional 362 shares during the period. Finally, Clear Creek Financial Management LLC raised its stake in Thermo Fisher Scientific by 211.7% during the fourth quarter. Clear Creek Financial Management LLC now owns 2,104 shares of the medical research company’s stock worth $1,095,000 after acquiring an additional 1,429 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several analyst reports. Barclays dropped their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Royal Bank of Canada dropped their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $655.64.

Thermo Fisher Scientific Trading Down 1.4 %

NYSE TMO opened at $598.40 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The stock has a market cap of $228.89 billion, a price-to-earnings ratio of 37.52, a PEG ratio of 3.89 and a beta of 0.76. The firm’s 50 day moving average price is $541.37 and its two-hundred day moving average price is $570.96.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 29,000 shares of company stock worth $15,859,540 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.